Skip to main content
. 2020 Jun 15;12(6):1579. doi: 10.3390/cancers12061579

Table 2.

Inhibitors of the UPS.

Inhibitor Target Reference
PYR-41 E1 enzyme [248,249]
MLN7243 E1 enzyme [250]
MLN4924 E1 enzyme [251]
Compound 4b E1 enzyme [252]
PYZD-4409 E1 enzyme [253]
Leucettamol A E2 enzyme [254]
Manadosterols A and B E2 enzyme [255]
CC0651 E2 enzyme [256]
Nutlins and derivatives, RITA, MI-219, Syl-155, MI-63, PRIMA-1, HLI98, HLI373, MEL23 and MEL24, ATSP-7041, NSC207895 Mdm2/Mdmx/p53-mediated E3 ligase enzyme [257,258,259,260,261,262,263,264,265,266,267]
Oridonin, SCF-12, ZL25, Compound A, Erioflorin, GS143, SMER3, TAME, Apcin SCF E3 ligase [268,269,270,271,272,273,274,275,276]
Bortezomib, CEP-18770, Carfilzomib (PR-171), ONX-0912, PR-047, MLN9708 and MLN2238 (Ixazomib), Marizomib (NPI-0052) Proteasomal inhibitors [277,278,279,280,281,282,283]